AIPT - Precision Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9500
-0.0101 (-1.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.9601
Open0.9500
Bid0.92 x 2200
Ask1.10 x 800
Day's Range0.9260 - 0.9600
52 Week Range0.6000 - 1.5800
Volume28,143
Avg. Volume69,075
Market Cap13.62M
Beta (3Y Monthly)3.04
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateMar 14, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has received an order from its Australian distributor for three STREAMWAY system units to be placed in a “center of excellence” in an emerging orthopedic department at Wangaratta Hospital in Victoria, Australia. The three units are a significant addition to Skyline’s presence in Australia and are placed in conjunction with its Australian distributor, Device Technologies, AU (https://www.device.com.au). “We are particularly pleased to be introducing the STREAMWAY system to the Victoria market, as it represents Australia’s second-most densely-populated region.  More importantly, the Wangaratta Hospital will serve as a center of excellence through which Device Technologies can effectively demonstrate the system to potential customers in a real-world application,” commented Dr. Carl Schwartz, chief executive officer of Precision Therapeutics.

  • GlobeNewswire13 days ago

    Precision Therapeutics’ TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers.  The company will utilize this discovery to further develop its proprietary TumorGenesis system for Cancer Cell Capture and Culture, which permits screening of drugs against the cancers cells.  The TumorGenesis system enables cells grown outside the body to behave as though they were present in a patient, potentially making the drug screening process more predictive. The TumorGenesis system, which the Company believes represents a paradigm shift in the way drug discovery is conducted, relies on the ability to grow tumors outside the body that will have the same genotype as a cancer mutation.  This methodology will allow pharmaceutical developers to create therapies that are unique to a particular patient’s tumor.  The biomarkers identified by TumorGenesis for these types of thyroid cancer involve the sequencing of the peptides that reside on the surface of the tumor cell.

  • GlobeNewswire24 days ago

    Precision Therapeutics’ Skyline Medical Division Widens Global Reach Through New Taiwanese Distribution Agreement with Winner Scientific

    MINNEAPOLIS, Jan. 25, 2019 -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of.

  • ACCESSWIRE27 days ago

    Precision Therapeutics Has Groundbreaking Approach to Personalized Cancer Treatment, Reports CEOCFO Magazine

    BOCA RATON, FL / ACCESSWIRE / January 22, 2019 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (AIPT). Precision Therapeutics is bringing ''true personalized oncology,'' Dr. Schwartz explained to CEOCFO's Bud Wayne.

  • GlobeNewswirelast month

    Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz, has made an additional investment of $1,000,000 in the Company, effective January 8, 2019. Of this investment, $950,000 was a loan under an amended and restated promissory note, which now covers advances of $1,320,000, including a previous loan Dr. Schwartz made in November 2018. As part of the investment, which is detailed in a Form 8-K filed with the United States Securities and Exchange Commission on January 14, 2019, Mr. Schwartz also received additional warrants to purchase Company common stock.

  • GlobeNewswirelast month

    Precision Therapeutics’ Skyline Medical Division Significantly Expands Footprint in New England With Sale of Six STREAMWAY Systems to Yale University Ambulatory Outpatient Surgical Center

    Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has completed the sale of six STREAMWAY systems to the new Yale New Haven Health Care Surgery Center in Guilford, Conn., a subsidiary of Yale University. The six-unit sale represents one of the company’s largest single-center sales to date. The health system has opted to install the STREAMWAY system in each of its six surgical suites, demonstrating confidence in the utility of Skyline’s STREAMWAY technology in the facility, currently under construction.

  • ACCESSWIRE6 months ago

    Skyline Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Skyline Medical, Inc. (NASDAQ: AIPT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...